UPDATE: MannKind (MNKD) May Not Be Able to Compete with Mylan's (MYL) EpiPen; Co. to Raise $10M - Feuerstein

August 31, 2016 1:37 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - August 31, 2016 1:50 PM EDT)

MannKind's (NASDAQ: MNKD) inhaled epinephrine may not be competition for Mylan's (NASDAQ: MYL) EpiPen, according to critic Adam Feurstein of theStreet. Earlier gains were tied to a NewTimes article discussing its EpiPen alternative.

In a follow-up tweet, Feuerstein suggested the company has plans to raise $10 million.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Momentum Movers, Rumors, Short Sales, Trader Talk

Related Entities

Adam Feuerstein

Add Your Comment